RxDoctor Payments Data

Melanie Majure, MD

Internal Medicine · Stanford, CANPI 1255639969

Payments from drug & device makers

$679,401in general payments, 2019–2025

Across 9 payments — averaging $75,489 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$679K
  • Gilead$96
  • Pfizer$77

What the payments were for

  • Food & beverage$10454%
  • Education$8946%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis4$679,228
Gilead2$96
Pfizer3$77

How this compares

$679,401 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$119,543
Medicare patients
156
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib29$260,170
PiqrayAlpelisib12$256,086
XareltoRivaroxaban11$7,619
Exemestane61$6,025
Anastrozole120$2,370
Letrozole85$2,128
Ibandronate Sodium24$620
Tamoxifen Citrate20$585
Gabapentin11$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPiqray$679,228$256,08612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →